S-1 Maintenance Therapy in Extensive Stage Small-Cell Lung Cancer—A Randomized Clinical Study

Keke Nie, MD1, Xiuhui Guo, MD2, Yunhong You, MD1, Xingjun Zhuang, MD3, Chunling Zhang, MD1, and Youxin Ji, MD1

Abstract
Small-cell lung cancer (SCLC) is a recalcitrant cancer for its dismal prognosis although extensive research had been done. Four to 6 cycles platinum-based chemotherapy is the mainstay treatment for the extensive-stage disease; but the role of maintenance treatment is not fully understood. This is a phase 2, open-label study. Patients with extensive-stage SCLC reaching an objective response or stable disease (SD) after induction chemotherapy were randomly assigned (1:1) with a minimization procedure. One group received oral S-1 and the other group received placebo as maintenance treatment until disease progression or unacceptable toxicities. The primary end point of this study was progression-free survival (PFS), and the secondary end points were overall survival (OS), response rates, and toxicities. This study was based on earlier work, the preliminary results was reported on 2019 ASCO annual meeting. A total of 89 patients were enrolled, of whom 45 received S-1 maintenance therapy and 44 received placebo. The median PFS and OS were 6.35 months and 10.82 months in the S-1 group, as compared to 5.98 months and 10.09 months in the placebo group. The PFS was 7.2 months and 5.3 months, and OS was 12.9 months and 10.9 months in patients with an objective response compared to in patients with SD after induction chemotherapy, respectively. S-1 maintenance therapy did not prolong PFS or OS in patients with extensive-stage SCLC; tumor regression rate was the prognostic factor of PFS or OS. Further research with novel agents in the maintenance setting is warranted.

Keywords
S-1, maintenance therapy, extensive-stage small-cell lung carcinoma, tumor regression rate

Received September 02, 2019. Received revised January 12, 2020. Accepted for publication March 31, 2020.

Introduction
Lung cancer is the leading cause of cancer death globally as well as in China,1 10% to 15% of them are small-cell lung cancer (SCLC).2,3 About 80% patients of SCLC are in extensive stage at diagnosis, of them, the 5-year survival rate is only 1% to 2% even though tremendous studies on it in recent 3 decades.1,4 Four to 6 cycles chemotherapy with EP (cisplatin/carboplatin and etoposide) or IP (cisplatin/carboplatin and irinotecan) is the mainstay treatment for the extensive-stage SCLC; despite response rates of 60% to 70%, a median overall survival (OS) is approximately 10 months.5,6 Four to 6 cycles chemotherapy combined and/or maintained with programmed cell death-ligand 1 (PD-L1) monoclonal antibody (atezolizumab or durvalumab) treatment had very limited benefit on response rate, progression-free survival (PFS), and OS compared to chemotherapy alone.7,8 Therefore, to elicit a cost-effective...
maintenance agent for extensive-stage SCLC after chemotherapy is critical important.

S-1 (TS-1, Taiho Pharmaceutical Co) is a novel oral dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine based on a biochemical modulation of 5-fluorouracil (5-FU), which was developed in 1990s for the treatment of gastric cancer. It contains tegafur (FF) and 2 types of enzyme inhibitor, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate (Oxo), in a molar ratio of 1:0.4:1. In pharmacokinetic studies, S-1 showed high 5-FU concentration in blood for long periods of time. S-1 worked well in local advanced and metastatic gastric cancer and also showed high efficacy with tolerable toxicity in non-small cell lung cancer. How works and the roles of maintenance therapy of S-1 in SCLC are not fully understood. We carried out a preliminary study in patients with extensive-stage SCLC, to compare the efficiency and toxicities of S-1 maintenance therapy with observation. This study was retrospectively registered on ClinicalTrials.gov (NCT03769935) on December 10, 2018, and the preliminary results of this study were reported on 2019 ASCO annual meeting and published on J Clin Oncol 37, 2019 (suppl; abstr e20080).

Methods

Study Design and Patient Selection

This is a 3-center, open-labeled, randomized study. Enrolled patients were histologically or cytologically confirmed stage IV SCLC by the International Association for the Study of Lung Cancer (IASLC) seventh edition, age 18 to 80 years old, with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and treatment naive. Patients must have adequate bone marrow, renal, and hepatic function. Patients were required to have one or more evaluable target lesions which could be measured in one dimension according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Central nervous system metastases at screen were excluded from the study.

Computerized randomization was done by center of the Qingdao Central Hospital, Qingdao University using Microsoft Excel 2007 formula and was dispensed to researchers case by case. When patient was qualified to the trial and informed consent was signed, the trial center of Qingdao Central Hospital would be informed and randomization would be done. Study group was received S-1 25 mg/m² twice a day orally, and the other group was received placebo and regularly follow-up as control. Randomization was performed with dynamic balancing with respect to performance status, assessed using the World Health Organization performance scale measure activity, sex. S-1 treatment continued until: (1) the disease progression defined by RECIST version 1.1, (2) uncontrollable serious adverse effects or death, and (3) requested by patients or physician. On request was defined as physician’s request to stop, based on the patient’s condition was in dangerous if the trial continue. Dose adjustments and crossover were not allowed.

Patients would be withdrawn from the study if they suffered intolerable drug-related toxicities (Figure 1).

Induction chemotherapy were initiated with EP regimen (etoposide 100 mg/m² intravenous infusion on days 1, 2, 3 and cisplatin 75 mg/m² or carboplatin AUC 5 intravenous infusion on day 1) or IP regimen (irinotecan 65 mg/m² and cisplatin 30 mg/m² intravenous infusion on day 1 and day 8); every 21 days a cycle for total 4 to 6 cycles. Patients enrolled this study must have reached complete response (CR), or partial response (PR), or stable disease (SD) per RECIST version 1.1 following completion of 4 to 6 cycles of induction therapy. All eligible patients were randomly assigned into 2 groups, in a 1:1 ratio. Imaging data were evaluated and reviewed by Centralized Independent Review Committee. One time to reduce 20% of dosage of EP or IP chemotherapy was permitted if patients acquired grade III to IV toxicity; but no further dose reduction was permitted. S-1 dosage adjustment was not allowed.

Outcomes and Assessment

The primary end point of the study was PFS, measured from enrollment date to disease progression or death. The second end points were response rates, toxicities, and OS. Response rates were assessed using RECIST version 1.1, observed during trial period, classified into: CR (disappearance of tumor lesions), PR (a decrease of at least 30% in the sum of tumor lesions sizes), stable disease (steady state of disease), or progressive disease (an increase ≥20% in the sum of tumor lesions sizes). All adverse events were recorded and classified by grade according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. The quality of life was assessed by KPS and recorded as apparently improved (increase in KPS by ≥20 posttreatment), improved (KPS score increase ≥10), stable (no apparent change in KPS score), and reduced (KPS score decline ≥10).

Tumor measurements were performed at screening and every 6 weeks thereafter. The results were reviewed by Independent Review Committee of Qingdao Central Hospital. Patients’ compliance, treatment safety, and side effects were accessed at each check point on every 6 weeks.

Statistical Analysis

This was a superiority study. A sample size of 156 patients was calculated for each group, a type I error of 0.05 (one-side) and 80% power of test, and a 0.5 coefficient of variability at a 1:1 sample ratio of the 2 groups was assumed by us. The anticipated dropout rate was 10% and the actual value of coefficient of variability was likely to over 0.5, the optimum sample size would be 196 patients per group if hazard ratio (HR) was close to 0.85 in this study. The superiority would be established if the upper limit of 95% CI for the HR of S-1 versus placebo was less than 0.85 in the full analysis set.

Based on the Cox proportional hazards model, and taking into account the influence of gender (male or female), ECOG performance status score (0 vs 1 vs 2, and chemotherapy regimens,
HR and 95% CI) were calculated in the full analysis population. Progression-free survival and OS curves were analyzed using SigmaPlot 11 (Systat software Inc) Kaplan-Meier log-rank test, and the HRs using Cox proportional hazards model in the intention-to-treat principle to compare the S-1 maintenance treatment group with the placebo group. Interim analyses and report were planned at 12 months of the study in the protocol. Early stopping of the study was allowed if the interim analyses data indicated that the S-1 group was clearly superior or inferior to the placebo group. Ethical board would be informed if there was unexpected adverse event happening or protocol modified.

The response rate, symptom reduction, and treatment-related adverse events were assessed with Fisher exact test (all randomly assigned patients received at least one dose of study drug).

**Results**

A total of 121 patients were screened and 89 of them were enrolled into the study from January 2017 to November 2018. Thirty-two patients were excluded from the study because they did not meet the inclusion standard. The 2 groups were well balanced, with 45 patients were randomly assigned to the S-1 group, 44 patients were in the control group (Figure 1).

All recruited patients were Chinese. We analyzed enrolled patients’ age, performance status, according to centers with Fisher exact text, there was no significant difference. All patients were in stage IV according to the IASLC seventh edition staging system. A total of 71.9% of patients (64 of 89) were men, the median age was 67-year-old. All patients’ ECOG performance status scores were range in 0 to 2. The most common metastatic or recurrent sites after induction chemotherapy were lung, lymph nodes, adrenal gland, liver, and brain. The median follow-up time was 13.0 months and the last follow-up date was November 30, 2018 (Table 1).

Among 89 patients, of whom 45 received S-1 maintenance therapy and 44 received placebo. The median PFS was 6.35 months in the S-1 group, as compared to 5.98 months in the placebo group (HR for progression in the S-1 group, 1.057; 95% CI: 0.656-1.707; \( P = .820; \) Figure 2A). The median OS was 10.82 months in the S-1 group, as compared to 10.09 months in the placebo group (HR for death in the S-1 group, 0.860; 95% CI: 0.374-1.617; \( P = .905; \) Figure 2B).

**Figure 1.** Trial profile. Data of cutoff date were November 30, 2018. Overall survival data were obtained on November 30, 2018.
Tumor regression rate influenced patients’ survival. The PFS and OS in patients with CR or PR after induction chemotherapy were 7.2 months and 12.9 months compared to 5.3 months and 10.9 months in patients with SD, respectively (Figure 3A-B).

The main adverse effects of the S-1 group were hand and foot syndrome, including rash or acne, dry skin, and darkened skin color, the incidence of which was much higher in the S-1 group than the incidence in the placebo group, and there was a significant difference. The anorexia, vomiting, alopecia and fatigue were higher in the S-1 group compared with the placebo group; and the hematological toxicities were neutropenia, thrombocytopenia, and anemia; however, there was no significant difference between the 2 groups. One patient had interstitial lung disease (ILD) in each group, cancer cell infiltrated ILD was diagnosed by radiologists and oncologists. There was no treatment-related death in both groups (Table 2). Qualities of life of patients were also accessed between the 2 groups at baseline and at last follow-up, there was no significant difference.

**Discussion**

Four to 6 cycles EP or IP chemotherapy is the mainstay treatment for the extensive-stage SCLC; despite response rates of 60% to 70%, a median OS was approximately 10 months. The role of maintenance treatment is not fully understood and the prognosis remains poor. Many trials had evaluated maintenance therapy in extensive-stage SCLC, and most of them had failed in significant in clinical outcomes. The GOIRC-AIFA FARM6PMFMJ-phase III trial indicated bevacizumab plus cisplatin and etoposide in the first-line treatment of extensive-stage SCLC and then bevacizumab maintenance treatment had a statistically significant improvement in PFS, which, however, did not translate into a statistically significant increase in OS.

Another clinical trial showed that maintenance

---

**Table 1. Baseline Characteristics of All Enrolled Patients.**

| Characteristic                              | S-1 group (N = 45) | Placebo group (N = 44) | P value |
|---------------------------------------------|--------------------|------------------------|---------|
| Median age (range)—years                   | 68 (45-80)         | 65 (49-80)             | .966    |
| Age group, no (%)                           |                    |                        |         |
| <65 years                                   | 16 (35.6)          | 14 (31.8)              |         |
| ≥65 years                                   | 29 (64.4)          | 30 (68.2)              |         |
| Sex, no (%)                                 |                    |                        | .974    |
| Male                                        | 33 (73.3)          | 31 (70.5)              |         |
| Female                                      | 12 (26.7)          | 13 (29.5)              |         |
| Smoking status, no. (%)                    |                    |                        | .979    |
| Never                                       | 13 (28.9)          | 12 (27.3)              |         |
| Former                                      | 2 (4.4)            | 1 (2.3)                |         |
| Histology, no. (%)                          |                    |                        | .988    |
| Small cell carcinoma                        | 43 (95.6)          | 43 (97.7)              |         |
| Mixed cell carcinoma                        | 2 (4.4)            | 1 (2.3)                |         |
| Chemotherapy regimen, no (%)               |                    |                        | .975    |
| EP                                          | 31 (68.9)          | 33 (75%)               |         |
| IP                                          | 14 (31.1)          | 11 (15.7)              |         |
| Previous chemotherapy response, no (%)     |                    |                        | .984    |
| CR + PR                                     | 39 (86.7)          | 36 (81.8)              |         |
| SD                                          | 6 (13.3)           | 8 (18.2)               |         |
| EP or IP dose reduction                     | 8 (17.8)           | 8 (18.2)               | NA      |
| Previous PCI, no (%)                        | 27 (60.0)          | 27 (61.4)              | NA      |
| Metastatic or recurrent site, no (%)       |                    |                        | .776    |
| Lung                                        | 23 (51.1)          | 21 (47.7)              |         |
| Liver                                       | 8 (17.8)           | 9 (20.5)               |         |
| Adrenal gland                               | 11 (24.4)          | 10 (22.7)              |         |
| Lymph nodes                                 | 13 (28.9)          | 11 (25.0)              |         |
| Brain                                       | 5 (11.1)           | 5 (11.4)               |         |
| Other                                       | 9 (20.0)           | 7 (15.9)               |         |
| ECOG performance status, no (%)            |                    |                        | .983    |
| 0                                           | 5 (11.1)           | 5 (11.4)               |         |
| 1                                           | 35 (77.8)          | 36 (81.8)              |         |
| 2                                           | 5 (11.1)           | 3 (6.8)                |         |

Abbreviation: CR, complete response; ECOG, Eastern Cooperative Oncology Group performance status score, range from 0 to 5, with higher score reflecting greater disability; EP, Etoposide and cisplatin; IP, Irinotecan and cisplatin; PCI, prophylactic cranial irradiation; PR, partial response; SD, stable disease.

**Figure 2.** Kaplan-Meier analysis of progression-free survival (A) and overall survival (B) in the full analysis set. HR indicates hazard ratio.
apatinib was safe and achieved encouraging PFS and OS in extensive-stage SCLC; however, it was a single-arm retrospective study with fewer cases. The IMpower133 Clinical Trial, the median PFS was 5.2 months in the atezolizumab group and 4.3 months in the placebo group, respectively, which has been the only trial translating PFS into a statistically significant increasing in OS, revealed that atezolizumab plus carboplatin and etoposide resulting in significantly longer PFS and OS than chemotherapy. The CASPIAN trial was the newest clinical trial, in the immunotherapy group patients received up to 4 cycles of platinum–etoposide plus durvalumab followed by maintenance durvalumab every 4 weeks, which showed a significant improvement in OS, with an HR of 0.73. Median OS was 13.0 months in the immunotherapy group versus 10.3 months in the platinum–etoposide group. So the standard chemotherapy (EP) plus PD-L1 inhibitor (atezolizumab or durvalumab) then flowed by PD-L1 inhibitor maintenance treatment was recommended for extensive-stage SCLC; however, the median OS was prolonged just only about 2 months compared with the standard chemotherapy. Whether bevacizumab with PD-L1 inhibitor plus chemotheraphy would be an optimal combination in extensive-stage SCLC needs more clinical trials.

**Figure 3.** Kaplan-Meier analysis of progression-free survival (A) and overall survival (B) according to tumor response during induction chemotherapy. HR indicates hazard ratio.

**Table 2.** Summary of Adverse Events.

| Adverse events              | S-1 group (N = 45) | Placebo group (N = 44) | P value |
|----------------------------|-------------------|------------------------|---------|
|                            | Grade 1 or 2      | Grade 3 or 4           | Grade 5 |
| Number (percent)           |                   |                       |         |
| Rash or acne               | 26 (57.8)         | 6 (13.3)               | 0 (0)   | .002 |
| Diarrhea                   | 7 (15.6)          | 1 (2.2)                | 0 (0)   | .085 |
| Dry skin                   | 11 (24.4)         | 0 (0)                  | 0 (0)   | .008 |
| Darkened skin color        | 29 (64.4)         | 1 (2.2)                | 0 (0)   | NA   |
| Anorexia                   | 16 (35.6)         | 0 (0)                  | 0 (0)   | .015 |
| Nausea                     | 8 (17.8)          | 0 (0)                  | 0 (0)   | .059 |
| Vomiting                   | 3 (6.7)           | 1 (2.2)                | 0 (0)   | NA   |
| Constipation               | 6 (13.3)          | 1 (2.2)                | 0 (0)   | .031 |
| Alopecia                   | 23 (51.1)         | 9 (20.0)               | 0 (0)   | .455 |
| Neutropenia                | 8 (17.8)          | 0 (0)                  | 0 (0)   | .123 |
| Thrombocytopenia           | 6 (13.3)          | 3 (6.7)                | 0 (0)   | .125 |
| Anemia                     | 5 (11.1)          | 0 (0)                  | 0 (0)   | .138 |
| Fatigue                    | 11 (24.4)         | 0 (0)                  | 0 (0)   | .030 |
| ILD                        | 1 (2.2)           | 0 (0)                  | 0 (0)   | .500 |

Abbreviation: ILD, interstitial lung disease.

*The date of data cutoff was November 30, 2018. Multiple occurrences of the same adverse events in one patient were counted once at the highest grade for the preferred term. The incidence of treatment-related adverse events associated with any component of the trial regimen was shown.
S-1 at a dose of 80 mg/m²/d orally for 14 days every 3 weeks was effective and tolerable in non-SCLC. Because of its low toxicity and easy administration, maintenance therapy of S-1 was performed for patients with extensive-stage SCLC who did not have disease progression after first-line treatment in our study. The main adverse effects of the S-1 group were hand and foot syndrome, including rash or acne, dry skin, and darkened skin color, the incidence of which was much higher in S-1 group than the incidence in the placebo group, which were mild to moderate and higher than the placebo group, and there was a significant difference. The anorexia, vomiting, alopecia, and fatigue also higher in the S-1 group compared with the placebo group. The hematological toxicities were neutropenia, thrombocytopenia, and anemia, which were higher than the placebo group and were tolerated; however, there was no significant difference between the 2 groups.

In our study, the median PFS and OS in the S-1 group were 6.35 months and 10.82 months, and the median PFS and OS in the placebo group were 5.98 months and 10.09 months, respectively. There was no significant difference between the 2 groups. S-1 maintenance therapy did not prolong patients’ PFS or OS, but increased treatment-related adverse events; tumor regression rate was the main factor that influenced patients’ survival. The PFS and OS in patients with CR or PR after induction chemotherapy were 7.2 months and 12.9 months compared to 5.3 months and 10.9 months in patients with SD, respectively. Standard of first-line treatment with platinum-based chemotherapy for extensive-stage SCLC, a median OS was in range of 9 to 11 months, which was the same in our study.

Conclusion
S-1 maintenance therapy in patients with extensive-stage SCLC after induction chemotherapy was safe but did not prolong PFS or OS. Tumor regression rate after induction therapy was the prognostic factor of PFS and OS. Further research with novel agents in the maintenance setting and maintenance therapy after second-line chemotherapy are needed in the future.

Authors’ Note
K.N., C.Z., and Y.J. designed the study. X.G., Y.Y., and X.Z. did patients’ follow-up. Y.J. did statistical analysis and prepared figures. K.N. helped to write the manuscript. All authors read and approved the final manuscript. All patients’ written consents were obtained before randomization (When patient was qualified to the trial and informed consent was signed, the trial center of Qingdao Central Hospital would be informed and randomization would be done). This study was approved by the Ethics Committee of Qingdao Central Hospital of Qingdao University (QingdaoCH-161207-SCLC), performed in compliance with the provisions of Good Clinical Practice guidelines, the Declaration of Helsinki, and local laws. Informed consents were obtained from the selected patients before randomization.

Acknowledgment
The authors sincerely appreciate the superb help by Professor Zhengfu Zhang and Professor Hongyu Lin on imaging data collection at Department of Radiology, Qingdao Central Hospital, Qingdao University. The authors also thank Professor Wendy Wang of Feinstein Institute for Medical Research and Professor John Califra in New York helped in editing the manuscript.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Youxin Ji https://orcid.org/0000-0003-2303-8784

References
1. Oronsky B, Reid TR, Oronsky A, et al. What’s new in SCLC? A review [Internet]. Neoplasia. 2017;19(2):842-847. doi:10.1016/j.neop.2017.07.007
2. Yan X, Wang Q, Wang H, et al. Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study [Internet]. J Cancer Res Clin Oncol. 2019;145(1):235-240. doi:10.1007/s00432-018-2764-8
3. Trial GF, Tiseo M, Boni L, et al: Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial. J Clin Oncol. 2017;35(12):1281-1287.
4. Roviello G, Zanotti L, Cappelletti MR, et al. No advantage in survival with targeted therapies as maintenance in patients with limited and extensive-stage small cell lung cancer: a literature-based meta-analysis of randomized trials [internet]. Clin Lung Cancer. 2016;17(5):334-340. doi:10.1016/j.jclcc.2016.05.008
5. Cai H, Wang H, Li Z, Jiamao L, Jinming YU. The prognostic analysis of different metastatic patterns in extensive-stage small-cell lung cancer patients: a large population-based study. Future Oncol. 2018;14(14):1397-1407.
6. Beck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34(31):3740-3748.
7. Shames DS, Liu J, Ding B, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220-2229.
8. Paz-ares L, Dvorkin M, Chen Y, et al. Articles Durvalumab plus platinum—etoposide versus platinum—etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled. Lancet. 2019;394(10212):1929-1939.
9. Shirasaka T, Shimatato Y, Osshima H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7(9):548-557. [PMID28862723].pdf
10. Kenji Omura: Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in
the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol. (2003)8:132-138. doi:10.1007/s10147-003-0330-z

11. Chihara Y, Date K, Takemura Y, et al. Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer. Invest New Drugs. 2019;37(2):291-296.

12. Nie K, Zhang C, Lan K, et al. Preliminary study of S-1 maintenance therapy in extensive stage small-cell lung cancer. J Clin Oncol. 2019;37(suppl; abstr e20080).

13. Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):706-714.

14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [Internet]. Eur J Cancer. 2008;45(1):228-247. doi:10.1016/j.ejca.2008.10.026

15. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial [internet]. Biometrics. 1975;31(1):103-105.

16. National Cancer Institute. Common Terminology Criteria for Adverse Events v.4.0 (CTCAE). Accessed August 28, 2019. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm

17. Lu H, Jiang Z. Advances in antibody therapeutics targeting small-cell lung cancer. Adv Clin Exp Med. 2018;27(9):1317-1323.

18. Gadgeel SM, Pennell NA, Fidler J, et al. Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC) [Internet]. J Thorac Oncol. 2018;13(9):1393-1399. doi:10.1016/j.jtho.2018.05.002

19. Suzuki S, Karayama M, Inui N, et al. Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer [Internet]. Invest New Drugs. 2016:9. doi:10.1007/s10637-016-0365-4

20. Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res. doi:10.21037/tlcr.2018.01.16

21. Shao C, Jin F. Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: a seer Medicare Study. Cancer Med. 2019:1-10.